Prosensa (NASDAQ: RNA) is one of 183 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Prosensa to similar businesses based on the strength of its earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
This table compares Prosensa and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Prosensa and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Prosensa Competitors||$217.36 million||-$39.57 million||-66.74|
Prosensa’s competitors have higher revenue, but lower earnings than Prosensa. Prosensa is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent recommendations and price targets for Prosensa and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 31.16%. Given Prosensa’s competitors higher possible upside, analysts clearly believe Prosensa has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Prosensa competitors beat Prosensa on 5 of the 8 factors compared.
Prosensa Company Profile
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company’s primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. The Company’s clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company’s platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
Receive News & Ratings for Prosensa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prosensa and related companies with MarketBeat.com's FREE daily email newsletter.